# MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

> **NCT05114213** · PHASE2 · TERMINATED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **RADIATION:** SBRT
- **DRUG:** SOC chemotherapy

## Key facts

- **NCT ID:** NCT05114213
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-15
- **Primary completion:** 2025-11-11
- **Final completion:** 2025-11-11
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Low accrual, close out in November 2025
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05114213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05114213, "MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05114213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*